Market Size & Forecast Report - 2025 to 2030

The global bone biopsy market size was valued at around USD 0.3 billion in 2024 and projected to grow at a significant CAGR of over 6% during the forecast period from 2025 to 2030. The market is experiencing steady growth, driven by the rising prevalence of bone cancers, bone infections, and metabolic bone disorders, along with the increasing demand for minimally invasive diagnostic procedures. Bone biopsy is a critical diagnostic tool used to detect bone abnormalities, tumors, osteoporosis, and infections, thereby supporting early detection and effective treatment planning. Technological advancements in biopsy needles and imaging guidance systems, coupled with the growing adoption of outpatient and image-guided biopsy procedures, are further boosting market expansion. Additionally, the increasing geriatric population, higher incidence of orthopedic conditions, and rising awareness about cancer diagnostics are expected to fuel market growth in the coming years.

Key Findings:

• The global bone biopsy market was valued at ~USD 0.3 billion in 2024, growing at a CAGR of over 6% (2025–2030).
• Growth is driven by rising bone cancers, infections, metabolic disorders, and an aging population.
• Minimally invasive, image-guided needle biopsies dominate due to efficiency and patient comfort.
• Cancer diagnosis is the largest application segment, especially for primary and metastatic tumors.
• Technological advancements (robotic systems, vacuum-assisted needles, CT/MRI guidance) are boosting adoption.
• North America leads the market, while emerging regions (Asia-Pacific, Latin America, Middle East) show rapid growth.
• Market challenges include regulatory hurdles, high costs, and limited skilled clinicians.
• Opportunities exist in automation, advanced devices, digital pathology, and molecular diagnostics.

Bone Biopsy Market Key Drivers:

The bone biopsy market is primarily driven by the increasing prevalence of bone-related disorders such as bone cancer, osteoporosis, and bone infections. According to the World Health Organization (WHO), osteoporosis affects an estimated 200 million people globally, with 1 in 3 women and 1 in 5 men over the age of 50 experiencing osteoporotic fractures. This rising burden of skeletal diseases has heightened the demand for accurate diagnostic techniques, where bone biopsy plays a key role in confirming abnormalities and guiding treatment. Moreover, the surge in cancer cases, particularly metastatic cancers that spread to the bone, is further fueling the need for bone biopsies as they provide critical histological insights for treatment planning.

Another major driver is the growing adoption of advanced and minimally invasive diagnostic procedures. Innovations in biopsy needles, image-guided technologies such as CT and MRI, and robot-assisted biopsy systems are making procedures safer, quicker, and more precise, thereby increasing acceptance among patients and healthcare providers. For instance, in 2022, research highlighted that image-guided bone biopsies showed over 95% diagnostic accuracy in detecting bone metastases, reinforcing their clinical value. Additionally, the global aging population, with the United Nations projecting that people over 65 will make up 16% of the world’s population by 2050, is expected to significantly contribute to the demand for bone biopsy procedures, as older adults are more prone to bone disorders.

Emerging Trends Shaping the Bone Biopsy Market Growth:

Shift Toward Minimally Invasive and Image-Guided Biopsies

One of the most significant trends is the growing preference for minimally invasive procedures compared to traditional open biopsies. Closed or percutaneous methods, especially needle biopsies, are gaining traction because they cause less trauma, involve shorter recovery times, and reduce hospitalization costs. The integration of imaging modalities such as CT scans, MRI, and ultrasound is making bone biopsy procedures far more accurate. Image guidance allows clinicians to precisely target lesions, improve diagnostic yield, and lower the risk of sampling errors. This trend is strongly linked to the global rise in demand for outpatient and day-care procedures, which are less stressful for patients and more cost-effective for healthcare systems.

Technological Innovation and Automation

Biopsy device manufacturers are focusing on innovation to improve patient safety, clinician ease of use, and diagnostic accuracy. Advanced systems such as vacuum-assisted biopsy devices, coaxial needle systems, and single-use sterile kits are being developed to enhance sampling efficiency. At the same time, automation and robotics are making their way into biopsy procedures. Robotic-assisted guidance systems are increasingly used to support clinicians in needle placement with unmatched precision. Future advancements such as augmented reality overlays and AI-driven real-time feedback tools could further revolutionize how biopsies are performed. These technological developments are expected to increase adoption, particularly in hospitals and specialized cancer centers.

Growth of Digital Pathology and Molecular Diagnostics

The scope of bone biopsy is expanding beyond simple histopathology. Today, tissue samples are increasingly analyzed using digital pathology solutions, including whole-slide imaging and AI-based interpretation. Moreover, molecular diagnostic methods such as next-generation sequencing (NGS) are being applied to biopsy samples, enabling clinicians to detect genetic and molecular markers of diseases. This is especially important in oncology, where targeted therapies require highly specific information about tumor biology. The trend reflects the growing importance of personalized medicine, where biopsy results are not only diagnostic but also guide customized treatment plans for each patient.

Rising Adoption in Emerging Markets

While North America and Europe continue to dominate the market due to advanced healthcare infrastructure, emerging markets are becoming key growth hotspots. Countries in Asia-Pacific, Latin America, and the Middle East are witnessing rapid improvements in diagnostic facilities, increased government investment in healthcare, and rising awareness about early cancer detection and bone health. The growing incidence of bone-related disorders in these regions, combined with an expanding middle-class population that can afford advanced diagnostics, is fueling adoption. Multinational players are also increasingly targeting these markets with cost-effective biopsy devices tailored to local needs.

Challenges: Regulation, Training, and Costs

Despite the positive momentum, certain challenges persist in the bone biopsy market. Regulatory approval processes for biopsy devices are often lengthy and complex, varying across different regions, which can delay product launches. Another barrier is the lack of skilled radiologists and pathologists in several countries, especially when it comes to performing advanced image-guided biopsies. Cost remains a critical issue as well—highly advanced biopsy devices and imaging equipment are expensive, making them less accessible in resource-constrained healthcare settings. Manufacturers and healthcare providers are working to address these barriers through training programs, cost optimization, and collaborations with regulatory bodies.

Emerging Opportunities Reshaping the Bone Biopsy Markte’s Evolution:

One of the biggest opportunities lies in the rapid adoption of advanced and automated biopsy devices — especially in the U.S. and other mature markets — which promise higher precision, better patient comfort, and better diagnostic yields. For example, the BD Trek bone biopsy kit has seen a 139% sales increase in the U.S., and the number of healthcare facilities using it has tripled. Automatic biopsy drivers, single-use core needles, vacuum-assisted and ultrasound-guided devices are increasingly in demand, reflecting a shift toward procedural efficiency and safety. Device makers that can combine improvements in imaging guidance, automation, and ergonomic design will find strong openings for innovation and new product development.

Additionally, there is large growth potential in emerging regions (Asia-Pacific, Latin America, and parts of Africa and the Middle East) driven by improving healthcare infrastructure, rising incidence of bone-related diseases, and growing awareness of early diagnosis. For instance, reports project that Asia-Pacific will be among the fastest growing markets. Also, the geriatric population is increasing in many of these countries, bringing a higher burden of osteoporosis, metastatic bone conditions, and other skeletal disorders, all of which need accurate diagnostic tools. Moreover, partnerships (e.g. between multinational device firms and local distributors or hospitals) and regulatory simplification (e.g. fast-track clearance of biopsy kits with clear safety records) offer additional levers for companies to expand penetration in less-served markets.

Market Insights:

By Product Type: Needle Biopsy Segment Dominated the Bone Biopsy Market in 2024

The global bone biopsy market is bifurcated into product type, procedure type, guidance technology, application, end-user, and geography. On the basis of product type, the needle biopsy segment is the dominant product type in the market, holding the largest share compared to surgical biopsy, biopsy kits, biopsy guns, and others. Its dominance stems from the minimally invasive nature of the procedure, which reduces patient discomfort, lowers complication risks, and shortens recovery times. Needle biopsies are particularly valuable in diagnosing bone marrow disorders, metastatic lesions, and infections, making them a frontline diagnostic tool in both hospitals and outpatient centers. As healthcare systems increasingly prioritize cost-effective and patient-friendly approaches, needle biopsy has become the preferred choice, replacing more invasive surgical methods in many cases.

Continuous advancements in needle technology further strengthen this segment’s position. The development of vacuum-assisted and coaxial systems, along with improvements in precision through imaging guidance such as CT, MRI, and ultrasound, ensures that clinicians can obtain high-quality samples with fewer errors. The growing prevalence of bone cancers, osteoporosis, and other skeletal diseases—particularly in aging populations—has amplified the demand for needle-based biopsies. As a result, this segment not only dominates the market today but is also expected to sustain its lead in the coming years, driven by its efficiency, adaptability, and alignment with the global shift toward minimally invasive diagnostics.

By Application: The Cancer Diagnosis Sub-category Holds the Largest Share of Bone Biopsy Market

On the basis of application, the bone biopsy market is further segmented into cancer diagnosis, bone infection diagnosis, metabolic bone disorders, genetic disorders, and others. As of 2024, the cancer diagnosis segment is the dominant application in the market, capturing the largest share among all applications. This dominance is primarily due to the increasing prevalence of primary bone cancers and metastatic cancers that spread to the bone, such as breast, prostate, and lung cancers. Bone biopsies are critical in oncology for confirming malignancy, identifying tumor type, and determining histological and molecular characteristics, which directly inform treatment decisions. Minimally invasive bone biopsy procedures are especially valuable in cancer diagnosis, as they allow clinicians to obtain sufficient tissue for analysis while minimizing patient discomfort and procedural risk. The rising global cancer burden, coupled with growing awareness about early detection and personalized treatment, has solidified cancer diagnosis as the leading application segment.

The segment’s prominence is further reinforced by advances in imaging-guided biopsy techniques and needle technologies that improve diagnostic accuracy and patient outcomes. CT, MRI, and ultrasound guidance enable precise targeting of suspicious lesions, ensuring high-quality samples for histopathological and molecular analysis. Additionally, the adoption of molecular diagnostic techniques and next-generation sequencing from biopsy samples is increasing, providing oncologists with actionable insights for precision medicine. As cancer incidence continues to rise globally, and as diagnostic and therapeutic strategies evolve, the cancer diagnosis application segment is expected to maintain its dominant position in the bone biopsy market for the foreseeable future.

The bone biopsy market research report presents the analysis of each segment from 2020 to 2030 considering 2024 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2025 to 2030.

Historical & Forecast Period

• 2020-23 – Historical Year
• 2024 – Base Year
• 2025-2030 – Forecast Period

Bone Biopsy Market Segmentation:

By Product Type:

• Needle Biopsy
• Bone Biopsy Kits
• Biopsy Guns
• Surgical Biopsy
• Others

By Procedure Type:

• Closed (Percutaneous) Biopsy
• Open Biopsy

By Guidance Technology:

• Ultrasound-Guided Biopsy
• CT-Guided Biopsy
• MRI-Guided Biopsy
• Fluoroscopy or X-ray Guided Biopsy

By Application:

• Cancer Diagnosis
• Bone Infection Diagnosis
• Metabolic Bone Disorders
• Genetic Disorders
• Others

By End-User:

• Hospitals
• Diagnostic Laboratories
• Specialty Clinics
• Ambulatory surgical centers
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis: North America Holds the Largest Share of Bone Biopsy Market in 2024

Geographically, the North America dominated the global bone biopsy market in 2024, accounting for the largest share globally. This leadership is driven by the region’s well-established healthcare infrastructure, widespread availability of advanced diagnostic imaging technologies, and high adoption of minimally invasive procedures. Hospitals and diagnostic centers in the U.S. and Canada are increasingly using image-guided needle biopsy systems for both bone marrow and bone lesion sampling, which has enhanced the precision and safety of these procedures. Additionally, the high prevalence of bone-related disorders, including metastatic cancers, osteoporosis, and other skeletal diseases, fuels demand for bone biopsy as a critical diagnostic tool. The region also benefits from substantial healthcare expenditure, reimbursement support for advanced diagnostic procedures, and strong awareness among clinicians and patients about early detection.

North America’s dominance is further reinforced by continuous technological innovation and strong R&D activities. Companies in the region are focusing on developing advanced biopsy needles, vacuum-assisted systems, and integrated imaging guidance solutions, which further increase the efficiency and adoption of bone biopsy procedures. The presence of leading diagnostic device manufacturers and active collaborations between hospitals and research institutions accelerates market growth. Moreover, the growing geriatric population, coupled with rising cancer incidence, ensures a steady demand for bone biopsy procedures. As a result, North America is expected to maintain its position as the largest and most technologically advanced market in the global bone biopsy landscape over the coming years.

Competitive Landscape:

Some of the prominent market players operating in the global bone biopsy market are BD (Becton, Dickinson and Company), Medtronic, Abbott Laboratories, Stryker Corporation, and Olympus Corporation. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• BD (Becton, Dickinson and Company)
• Medtronic
• Abbott Laboratories
• Stryker Corporation
• Olympus Corporation
• Hologic, Inc.
• Thermo Fisher Scientific
• Siemens Healthineers
• GE Healthcare
• Philips Healthcare
• Canon Medical Systems
• Boston Scientific Corporation

Key Questions Answered by Bone Biopsy Market Report

• Global bone biopsy market forecasts from 2025-2030
• Regional market forecasts from 2025-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2025-2030 covering 15 major countries from the regions as mentioned above
• Bone biopsy submarket forecasts from 2025-2030 covering the market by product type, procedure type, guidance technology, application, end-user, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level bone biopsy markets from 2025-2030
• Competitive Landscape and market positioning of top 10 players operating in the market